Compare INAB & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INAB | BFRI |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United States |
| Employees | N/A | 94 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 13.2M |
| IPO Year | 2020 | N/A |
| Metric | INAB | BFRI |
|---|---|---|
| Price | $1.44 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $2.75 |
| AVG Volume (30 Days) | 40.1K | ★ 381.2K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $0.57 |
| 52 Week High | $2.73 | $1.21 |
| Indicator | INAB | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 52.43 |
| Support Level | $1.32 | $0.77 |
| Resistance Level | $1.53 | $1.14 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 60.31 | 48.73 |
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.